{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"The RP2D of Ixazomib was determined in Part 1 (dose escalation) on the basis of the totality of safety, tolerability, pharmacokinetics (PK) and pharmacodynamic data observed in Cycle 1 and beyond.","groups":[{"description":"All participants who received ixazomib 0.24 mg/m\\^2, 0.48 mg/m\\^2, 0.8 mg/m\\^2, 1.2 mg/m\\^2, 1.68 mg/m\\^2, 2 mg/m\\^2 or 2.23 mg/m\\^2 in dose-escalation cohorts.","id":"OG000","title":"Ixazomib (All Groups)"}],"paramType":"NUMBER","populationDescription":"Safety population included all participants who received at least 1 dose of ixazomib.","reportingStatus":"POSTED","timeFrame":"Cycle 1 through Cycle 39 (Up to 28.3 months)","title":"Recommended Phase 2 Dose (RP2D) of Ixazomib","type":"PRIMARY","unitOfMeasure":"mg/m^2"}